Natalie Grover, MD, assistant professor in the division of hematology and clinical director of the cell therapy program in the Lineberger Comprehensive Cancer Center, discusses her research on anti-CD30 CAR-T therapy for patients with relapsed/refractory Hodgkin lymphoma in a new video featured on the Oncology Learning Network.
Following is an excerpt from the transcript:
“CAR-T cells targeting CD19 have shown remarkable efficacy in B‑cell lymphomas. This has sparked interest in exploring other targets in lymphoma. CD30 is universally expressed in Reed‑Sternberg cells. These are the malignant cells in classical Hodgkin lymphoma.
“In addition, targeting CD30 has minimal on‑target, off‑tumor toxicity because it has low expression in normal tissue. Its efficacy and safety as a target has also been demonstrated by the success of the drug brentuximab vedotin.
“Although the majority of patients with Hodgkin lymphoma are cured with first‑line therapy, a proportion of patients have relapsed or refractory disease, and prognosis is worse for those patients.”
Grover says CD30‑directed CAR-T cells have promising clinical activity in relapsed or refractory Hodgkin lymphoma with a good safety profile and should be explored further in larger trials.
Read the transcript or watch the video.